| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5466699 | ASTRAZENECA | Indolyl compounds for treating migraine |
Nov, 2012
(11 years ago) | |
|
US5466699 (Pediatric) | ASTRAZENECA | Indolyl compounds for treating migraine |
May, 2013
(11 years ago) | |
Zomig-Zmt is owned by Astrazeneca.
Zomig-Zmt contains Zolmitriptan.
Zomig-Zmt has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Zomig-Zmt are:
- US5466699
- US5466699*PED
Zomig-Zmt was authorised for market use on 13 February, 2001.
Zomig-Zmt is available in tablet, orally disintegrating;oral dosage forms.
The generics of Zomig-Zmt are possible to be released after 14 May, 2013.
Drugs and Companies using ZOLMITRIPTAN ingredient
Market Authorisation Date: 13 February, 2001
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
More Information on Dosage
ZOMIG-ZMT family patents
